Navigating the complex landscape of rare disease financial aid in India is difficult for many families. Recently, the Centre informed the Delhi High Court that a child with LRBA deficiency is ineligible for support. This is because the genetic condition does not feature on the list of notified rare diseases under NPRD 2021. Consequently, this decision highlights the strict regulatory boundaries governing medical funding for those pursuing a career in specialized paediatric care.
Challenges in Securing Rare Disease Financial Aid
The NPRD 2021 offers financial assistance up to Rs 50 lakh for patients with eligible conditions. However, the government currently restricts this support to 63 notified rare diseases. Because LRBA deficiency is not on this official list, authorities denied the family’s funding request. Consequently, the family sought judicial intervention to secure funding for a life-saving bone marrow transplant. Nevertheless, the government maintains that it cannot extend benefits beyond the established legal framework.
The Government’s Stance on Policy and Jurisdiction
In its affidavit, the Ministry of Health and Family Welfare argued against judicial modification of policy. It stated that expanding the list of covered diseases is strictly an executive decision. Furthermore, the Centre emphasized that the Union has no obligation to underwrite all medical costs. Since public health falls primarily under state jurisdiction, the Centre urged the High Court to dismiss the petition.
Clinical Presentation and Policy Framework
LRBA deficiency is a severe, life-threatening genetic immune disorder that causes recurrent infections. For patients with this condition, a bone marrow transplant often represents the only curative option. Under the existing NPRD framework, 15 Centres of Excellence manage diagnoses and coordinate funding requests. Unfortunately, patients cannot access these financial resources unless the government adds their condition to the list, a reality often discussed by experts in paediatric neurology.
Frequently Asked Questions
Q1: What is LRBA deficiency and why is it serious?
LRBA deficiency is a rare genetic immune disorder that impairs the body’s immune regulation. It leads to recurrent infections, severe anemia, and life-threatening autoimmune complications, often requiring a transplant.
Q2: Who is eligible for financial assistance under NPRD 2021?
Under the NPRD 2021, patients suffering from any of the 63 notified rare diseases can receive financial support. Specifically, eligible individuals can receive up to Rs 50 lakh for treatment at designated Centres of Excellence. For medical professionals aiming to better understand such complex conditions, enrolling in an International Post Graduate Program In Pediatrics can provide essential clinical insights.
References
- Delhi HC told rare disease patient not eligible for aid under NPRD 2021, Centreopposes plea – ETHealthworld
- Delhi HC hears plea seeking urgent rare disease funding for 3-year-old girl’s treatment – Hindustan Times
- National Policy for Rare Diseases, 2021 – Ministry of Health and Family Welfare, Government of India
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.